Amylyx Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	138	994	2,448	-	-	-
Market Cap Growth	-	-59.40%	-	-	-	-
Enterprise Value	-230	626	2,107	-96	-12	12
PE Ratio	2.90	20.17	-12.34	-	-	-
PS Ratio	0.36	2.61	110.13	-	-	-
PB Ratio	0.32	2.29	7.19	-	-	-
P/FCF Ratio	12.90	93.08	-13.42	-	-	-
P/OCF Ratio	11.55	83.38	-13.61	-	-	-
EV/Sales Ratio	1.64	1.64	94.77	-337.92	-17.91	8.30
EV/EBITDA Ratio	11.30	11.30	-10.69	1.10	0.29	-0.95
EV/EBIT Ratio	11.53	11.53	-10.66	1.10	0.29	-0.95
EV/FCF Ratio	58.63	58.63	-11.55	1.28	0.32	-1.11
Debt / Equity Ratio	0.01	0.01	0.02	-	-0.02	-0.59
Debt / EBITDA Ratio	0.08	0.08	-0.03	-	-0.04	-1.20
Debt / FCF Ratio	0.40	0.40	-0.03	-	-0.04	-1.40
Quick Ratio	5.02	5.02	7.79	5.54	1.78	0.68
Current Ratio	5.66	5.66	8.20	6.03	1.86	0.71
Asset Turnover	0.83	0.83	0.08	0.01	0.08	-
Interest Coverage	-	-	-	-	-17.48	-9.75
Return on Equity (ROE)	12.40%	12.40%	-86.40%	80.70%	91.80%	-
Return on Assets (ROA)	10.70%	10.70%	-74.00%	-146.90%	-488.10%	-
Return on Capital (ROIC)	8.04%	8.04%	-58.04%	54.70%	59.73%	130.00%
Earnings Yield	35.78%	4.96%	-8.10%	-	-	-
FCF Yield	7.75%	1.07%	-7.45%	-	-	-
Buyback Yield / Dilution	-19.65%	-19.65%	-788.13%	-8.37%	-3.20%	-
Total Shareholder Return	-19.65%	-19.65%	-788.13%	-8.37%	-3.20%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).